Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05329129 · ClinicalTrials.gov registry record
OssDsign® Spine Registry Study ("Propel")
A clinical trial of Degenerative Disc Disease and Spinal Stenosis, sponsored by OssDsign.
- Recruiting
- Registry status
- 450
- Enrollment target
- 13
- Study locations
NCT05329129: Recruiting study of Degenerative Disc Disease and Spinal Stenosis, sponsored by OssDsign.
NCT05329129 is a study of Degenerative Disc Disease and Spinal Stenosis that is actively recruiting participants, run by OssDsign. The registered enrollment target is 450 participants, above the 158-participant average among 42 other Degenerative Disc Disease trials with a reported enrollment target (185% higher). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05329129, a study of Degenerative Disc Disease and Spinal Stenosis, is actively recruiting participants, sponsored by OssDsign.
- RECRUITING
- Registry status
- 450 participants
- Enrollment target
- 13
- Study locations
Study Summary
The purpose of this multi-center, prospective, observational registry is to gather information on the clinical outcomes and real-world use of commercially available bone graft substitutes manufactured by OssDsign® AB, in patients who require spine fusion.
Primary Outcome
Assessment of the rate of bone fusion via Computerized Tomography (CT)/x-ray based on evidence of continuous bone bridging from the superior to the inferior vertebral body at the target level.
Conditions Studied
Interventions
- DEVICE OssDsign® Catalyst
Study Locations (13)
Connecticut
- Orthopedic Associates of Hartford - Hartford
- Central Connecticut Neurosurgery and Spine - New Britian
- Yale Center for Clinical Investigation, Yale School of Medicine - New Haven
California
- Community Health Partners Neuroscience - Fresno
- San Diego Neurosurgery - San Diego
Florida
- Minimally Invasive Spine Center of South Florida - Miami
- Foundation for Orthopaedic Research and Education - Tampa
Georgia
- Northeast Georgia Medical Center - Gainesville
Illinois
- Carle Foundation Hospital, NeuroScience Institute - Urbana
Kentucky
- Orthopaedic Institute of Western Kentucky - Paducah
Maryland
- OrthoBethesda Research Foundation - Bethesda
Minnesota
- Twin Cities Orthopedics - Edina
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2022-03-23 |
| Est. Completion | 2027-04-01 |
What NCT05329129 shows while recruiting
NCT05329129 is an observational study that tracks outcomes without assigning an intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, above the 158-participant average among 42 other Degenerative Disc Disease trials with a reported enrollment target (185% higher).
The record links to 2 conditions, with Degenerative Disc Disease appearing as the primary indexed condition, and to 1 intervention - of which OssDsign® Catalyst is the first listed.
NCT05329129 lists 13 locations in 9 states (Connecticut, California, Florida).
Frequently Asked Questions
What is clinical trial NCT05329129 about?
NCT05329129 is a clinical study titled "OssDsign® Spine Registry Study ("Propel")". The purpose of this multi-center, prospective, observational registry is to gather information on the clinical outcomes and real-world use of commercially available bone graft substitutes manufactured by OssDsign® AB, in patients who require spine fusion.
What is the current status of trial NCT05329129?
This trial is currently recruiting. The enrollment target is 450 participants. The study started on 2022-03-23. Estimated completion is 2027-04-01.
What conditions does trial NCT05329129 study?
This clinical trial studies the following conditions: Degenerative Disc Disease, Spinal Stenosis.
What interventions are being tested in trial NCT05329129?
The interventions under investigation include: OssDsign® Catalyst (DEVICE).
Who is sponsoring clinical trial NCT05329129?
This trial is sponsored by OssDsign, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05329129 being conducted?
This trial has 13 study locations across California, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Degenerative Disc Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05329129's enrollment target sits among peer trials
450 4th of 42 higher than 39 of 42 other Degenerative Disc Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Degenerative Disc Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease
RECRUITING · Phase 3
-
LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)
RECRUITING · Phase 1
-
Investigation of DEXA-C Anterior Cervical Interbody System
RECRUITING · NA
-
Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion
RECRUITING · NA
-
Trial for Treating Painful Degenerative Disc Disease
RECRUITING · NA
-
Evaluation of Safety and Effectiveness of Primary Hybrid Construct of Mobi-C and ACDF in the Treatment of Two-level Symptomatic Degenerative Disc Disease in the Cervical Spine.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI